<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320229</url>
  </required_header>
  <id_info>
    <org_study_id>ABCX-LD</org_study_id>
    <nct_id>NCT00320229</nct_id>
  </id_info>
  <brief_title>Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Sanitaria Ospedaliera</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Sanitaria Ospedaliera</source>
  <brief_summary>
    <textblock>
      The aim of our study was to demonstrate that, during a percutaneous coronary intervention,
      even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid
      thrombus resolution and clinical improvement without concomitant differences in hemorrhagic
      complications
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients both with acute myocardial infarction and unstable angina are prone to extensive
      intracoronary thrombosis, leading to acute deterioration during percutaneous coronary
      intervention or thrombosis of the device despite therapy. Intracoronary use of abciximab has
      reported favourable results. We randomly assigned 84 patients to intracoronary half abciximab
      bolus (group A) and to standard regimen (group B).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2004</start_date>
  <completion_date>July 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>84</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abciximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presenting with unstable angina

          -  presenting with acute myocardial infarction

          -  eligibility for percutaneous coronary intervention

        Exclusion Criteria:

          -  presenting with cardiogenic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mara Sansa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Interventional Cardiology - Ospedale Maggiore - Novara - Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiologia 2 - Emodinamica - Ospedale Maggiore</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2006</study_first_submitted>
  <study_first_submitted_qc>May 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <last_update_submitted>May 15, 2006</last_update_submitted>
  <last_update_submitted_qc>May 15, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2006</last_update_posted>
  <keyword>angioplasty</keyword>
  <keyword>stent</keyword>
  <keyword>abciximab</keyword>
  <keyword>Platelet Glycoprotein GPIIb-IIIa Complex</keyword>
  <keyword>myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

